AU2015200715A1 — Methods for treating HCV
Assigned to AbbVie Ireland ULC · Expires 2015-03-05 · 11y expired
What this patent protects
METHODS FOR TREATING HCV The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at leas…
USPTO Abstract
METHODS FOR TREATING HCV The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent I (ABT) or therapeutic agent 2 (=ABT-333) or therapeutic agent 3 (=ABT-072) or therapeutic agent 4 (ABT), and an inhibitor of cytochrome P450 (e.g., ritonavir).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.